Azzad Asset Management Inc. ADV Grows Stock Holdings in DexCom, Inc. $DXCM

Azzad Asset Management Inc. ADV grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 207.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,199 shares of the medical device company’s stock after purchasing an additional 8,905 shares during the period. Azzad Asset Management Inc. ADV’s holdings in DexCom were worth $888,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Norges Bank acquired a new position in DexCom during the second quarter worth $453,279,000. Groupama Asset Managment raised its holdings in shares of DexCom by 79,043.1% during the 2nd quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after acquiring an additional 4,011,438 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of DexCom by 106.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock worth $576,610,000 after acquiring an additional 3,410,858 shares during the period. Marshall Wace LLP boosted its position in shares of DexCom by 260.7% during the 2nd quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after acquiring an additional 2,762,504 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in shares of DexCom by 82.1% in the second quarter. Federated Hermes Inc. now owns 3,633,139 shares of the medical device company’s stock valued at $317,137,000 after purchasing an additional 1,638,407 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of analyst reports. JPMorgan Chase & Co. reduced their target price on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, October 31st. UBS Group reduced their price target on shares of DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Robert W. Baird set a $82.00 price objective on DexCom in a report on Friday, October 31st. Mizuho increased their price objective on DexCom from $75.00 to $78.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Morgan Stanley restated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $85.00.

DexCom Stock Up 0.3%

Shares of NASDAQ DXCM opened at $70.16 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $68.80 and its two-hundred day moving average is $70.07. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The firm has a market cap of $27.36 billion, a price-to-earnings ratio of 38.98, a PEG ratio of 1.25 and a beta of 1.49.

Insider Transactions at DexCom

In related news, Director Richard Alexander Collins sold 2,906 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the completion of the transaction, the director directly owned 35,088 shares in the company, valued at $2,071,946.40. This trade represents a 7.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the sale, the director owned 27,031 shares in the company, valued at $1,569,690.17. This trade represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.